Haleon plc: 2025 Q3 Trading Statement
30 October 2025: Haleon plc (the "Company" or "Haleon") today announces its Q3 trading statement for the year ending 31 December 2025 is available at: http://www.rns-pdf.londonstockexchange.com/rns/4049F_1-2025-10-29.pdf .
The Q3 trading statement will also be available on the Haleon website www.haleon.com/investors , and has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Dawn Allen, Chief Financial Officer at 9:00am GMT (10:00am CET) on 30 October 2025, which can be accessed at www.haleon.com/investors .
For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:
| UK: |
+44 (0) 808 189 0158 |
| US: |
+1 855 979 6654 |
| All other: |
+44 (0) 203 936 2999 |
| Passcode: |
407228 |
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors .
Amanda Mellor
Company Secretary
Enquiries
| Investors |
Media
|
||
| Jo Russell |
+44 7787 392441 |
Zo ë Bird |
+44 7736 746167 |
| Rakesh Patel |
+44 7552 484646 |
Victoria Durman |
+44 7894 505730 |
|
Email: [email protected] |
Email: [email protected] |
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com .
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.